Abstract: A coating film exhibiting excellent water and oil repellency is provided. The coating film comprises (a) calcium carbonate having an average particle diameter of 600-9,000 nm, (b) poly(vinyl alcohol), and (c) a copolymer including constituent units of a monomer having a C6 or lower perfluoroalkyl group.

Abstract: The present invention provides a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (hereinafter, referred to as HMB), which is excellent in solubility and easy to handle, and a process for producing the crystal. A crystal of a monovalent cation salt of HMB is precipitated in an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 9.0, and the crystal of a monovalent cation salt of HMB is thereafter collected from the aqueous solution.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.

Abstract: A liquid for cryopreserving a cell and a liquid for administration of a mammalian cell capable of cryopreserving a mammalian cell and effectively suppressing cell death after thawing, and a method for cryopreserving a mammalian cell using the cell cryopreservation liquid. The liquid is an isotonic solution that includes 2.0 to 6.0% (w/v) of trehalose or a derivative thereof, or a salt of the trehalose or the derivative, 4.0 to 7.0% (w/v) of dextran or a derivative thereof, or a salt of the dextran or the derivative, and DMSO or glycerin.

Abstract: Phenylimidazole compounds of formula (1) shown below and pharmaceutically acceptable salts thereof: Also disclosed are a pharmaceutical composition and a lipoprotein lipase activator, each containing one of the phenylimidazole compounds.

Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.

Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).

Abstract: An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation.

Abstract: There is provided a container or an equipment having low-protein adsorption properties, to be used for administering, storing, conveying or transporting protein or a composition including protein, or for producing protein or a composition including protein. A container or an equipment for producing protein or a composition including protein, wherein the surface of the container or the equipment in contact with protein or a composition including protein is formed of a fluororesin which is at least one fluororesin selected from a tetrafluoroethylene-hexafluoropropylene-based copolymer and a tetrafluoroethylene-perfluoroalkylvinyl ether-based copolymer, which has a melting point of 320° C. or less and which has a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, has remarkable low-protein adsorption properties.

Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).

Abstract: An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation.

Abstract: It is an object of the present invention to provide a nutritional composition for preventing diarrhea enabling ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form. A nutritional composition that is prepared by selecting a pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85% among pectins, and mixing the selected pectin with lipid, carbohydrate and protein, enables ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form.

Abstract: An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.

Abstract: It is an object of the present invention to provide a nutritional composition for preventing diarrhea enabling ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form. A nutritional composition that is prepared by selecting a pectin having a degree of esterification of 10 to 30%, a degree of amidation of 0 to 25%, and a degree of free acids of 64% or more and less than 85% among pectins, and mixing the selected pectin with lipid, carbohydrate and protein, enables ingestion or administration of nutritional ingredients while effectively preventing diarrhea, and is capable of stably keeping the viscosity when stored in a liquid form.

Abstract: The present invention provides a needle unit configured to be mounted to medical syringe, the needle unit including a needle member having a longitudinally extending inner space and having a needle hole formed in a side surface of a front end and an opening formed in a base end, the inner space being in communication with the outside through the needle hole and the opening, a base portion for supporting the base end of the needle member and communicating between the syringe and the inner space of the needle member by being attached to the syringe, a slide member movable along an outer peripheral surface of the needle member and capable of taking a first position to close the needle hole and a second position to uncover the needle hole in the base end portion side of the first position, a biasing member that biases the slide member from the second position side to the first position side; and a cap removably mounted to the base portion and is configured to cover the needle member.

Abstract: A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells.

Abstract: A coating film exhibiting excellent water and oil repellency is provided. The coating film comprises (a) calcium carbonate having an average particle diameter of 600-9,000 nm, (b) poly(vinyl alcohol), and (c) a copolymer including constituent units of a monomer having a C6 or lower perfiuoroalkyl group.

Abstract: It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like.

Abstract: The present invention provides a lid cover (1) of a medicine container (2) for preventing a medicine, which is air-tightly stored in a medicine container (2) that has a lid portion (22) that can be pierced with a needle (33), from leaking to an outside space when the medicine is suctioned using a syringe (3) having the needle (33), the lid cover (1) including a peripheral wall portion (10) that can be mounted to the lid portion (22) so as to surround a piercing face of the lid portion (22) that is pierced with the needle (33) and a ceiling face portion (50) that is continuous with an upper portion of the peripheral wall portion (10), and can be pierced with the needle (33), wherein the peripheral wall portion (10) and the ceiling face portion (50) are made of an elastic material, and are configured to air-tightly store the piercing face such that the piercing face is not exposed to the outside space in a state where the peripheral wall portion (10) is mounted to the lid portion (22), while also forming a clos

Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).